Thanks to some big-name deals over the past year, Ambrx could rake in nearly $1 billion in licensing for its antibody drug conjugates, but the company hasn't lost sight of its in-house development, now partnering with WuXi PharmaTech and a Chinese drugmaker to advance a breast cancer treatment.
Just a month after landing a $15 million payday for a deal with Astellas to collaborate on new antibody drug conjugates for cancer, the San Diego-based biotech Ambrx has scored another research pact--reaping another $15 million upfront from Bristol-Myers in exchange for a new oncology partnership.
San Diego-based Ambrx welcomed an influx of cash for the further development of its drug-delivery technology: antibody drug conjugates, or ADCs.
Astellas Pharma has wagered on antibody drug conjugate tech from the San Diego biotech startup Ambrx, paying $15 million upfront and committing up to $285 million more in their collaboration focused in oncology. And it's more proof that major pharma outfits are keen on the advantages of pairing targeted antibodies with potent drug payloads to treat cancer.
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it...
As antibody drug conjugates become more and more popular in the world of cancer drug development, Merck has inked a deal worth up to $303 million with San Diego's Ambrx to use the company's delivery tech.
The biotech, a Fierce 15 company way back in 2005, grabbed $15 million upfront and the promise of up to $288 million more from Merck as it puts its protein expertise to work in creating new "smart bomb" therapeutic programs for the pharma giant.
Bristol-Myers Squibb ($BMY) is handing Ambrx an upfront payment of $24 million to buy itself a ticket to ride on the La Jolla, CA-based biotech's discovery platform. Adding to a string of
The San Diego-based Ambrx will be forging ahead without a captain at the helm--at least for a short time. A spokesperson for the seven-year-old biotech-- a promising 2005 Fierce 15 company--tells
Wyeth Pharmaceuticals, and Ambrx have formed a discovery, development, and commercialization alliance covering protein drug candidates for three undisclosed targets in multiple therapeutic areas.